Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.

Necchi A, Raggi D, Giannatempo P, Alessi A, Serafini G, Colecchia M, Ali SM, Chung JH. Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. Eur J Cancer. 2018 06; 96:128-130.

View in: PubMed

collapse authors with profiles